Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation

Active, not recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

July 1, 2024

Study Completion Date

July 1, 2025

Conditions

OsteoporosisOsteoporosis, PostmenopausalOsteopeniaBone Loss

Interventions

DRUG

Zoledronic acid

Once-yearly infusion of zoledronic acid following denosumab discontinuation

Trial Locations (1)

University of Calgary, McCaig Institute for Bone and Joint Health, Calgary

All Listed Sponsors

lead

University of Calgary

OTHER